Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MK-7902-017 : A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Bowel<br/>CancersCancer LocationBowel
Cancers

Systemic therapy | Bowel (colorectum)Colorectum

Trial Overview Read MoreRead more

This Phase III trial is trying to understand whether a combination of targeted therapy (Lenvatinib) and immunotherapy (Pembrolizumab) is more effective than standard care in people with metastatic colorectal cancer.
 

This trial is treating patients with colorectal (bowel) cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment

Commercial Sponsor

Merck

Summary

This trial has experimental and active comparator arms. In the Experimental arm, participants will receive pembrolizumab (400mg, intravenously) on Day 1 of each 6-week (Q6W) Cycle for up to 18 cycles (up to approximately 2 years) in combination with lenvatinib (200mg, orally) once daily until progressive disease. In the Active Comparator arm, participants will receive the standard of care treatment: regorafenib (160mg, orally) once daily on Days 1 through 21 of each 4-week cycle OR TAS-102 (trifluridine and tipiracil hydrochloride) (35mg/m^2, orally) twice a day on Days 1 through 5 and Days 8-12 of each 4-week cycle until progressive disease.

Recruiting Hospitals Read MoreRead more

Epworth Hospital
Richmond
Mr Dave McKee
dave.mckee@epworth.org.au
03 9936 8043

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next